MSN: Study finds cost of brand-name epilepsy drugs nearly triples in eight years
UC expert says generic drugs typically are a safe, effective alternative
A new study found the cost for a year's supply of brand-name epilepsy drugs increased by 277% from 2010 to 2018, while the cost for a year's supply of generic epilepsy drugs decreased by 42% over the same time period.
Michael Privitera, MD, professor of neurology in the University of Cincinnati College of Medicine and director of the Epilepsy Center at the UC Gardner Neuroscience Institute, commented on the study for an article published by United Press International and MSN.
Privitera said he and his colleagues have performed "rigorous studies" that found no clinically important differences between generic and name-brand versions of one anti-seizure medication, lamotrigine.
The main approach to lowering prices for patients is to use generic drugs whenever possible, Privitera said, but some patients' seizures are only controlled with particular drugs that do not have generic equivalents.
Read the MSN story, originally published by United Press International.
Featured photo at top courtesy of Unsplash.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.